#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/0816cb6686751420365441adc6a28ced2d272f14/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
 DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
# DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
 DEFINE NAMESPACE NCIT           AS PATTERN "^C\d+$"
 DEFINE NAMESPACE OMIT           AS PATTERN "^\d{7}$"
###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
 # DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
 # DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 # DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
 # DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "28669544"}

SET Species = "10090"

SET Evidence = "Microglia, the innate immune cells of the central nervous system (CNS), provide constant surveillance for neural functioning (Nimmerjahnet al., 2005; Davalos et al., 2005)."
SET MeSHAnatomy = "Central Nervous System"
a(MESH:Microglia) isA bp(MESH:"Immunity, Innate")
a(MESH:Microglia) reg path(MESH:"Neural Pathways")
UNSET MeSHAnatomy

SET Evidence = "They coordinate various critical roles throughout life, assisting early neuronal development and circuit formation and maintaining brain homeostasis (Paolicelli and Gross, 2011; Tremblay et al., 2011;
Kettenmann et al., 2013)."
#they - microglia
a(MESH:Microglia) reg bp(GO:"nervous system development")
a(MESH:Microglia) reg bp(GO:"brain development")

SET Evidence = "As the primary source of phagocytes in the CNS, microglia engulf cellular debris upon programmed
apoptosis, remove excess synapses during neural circuit maturation, and clear the brain from potentially dangerous protein aggregates (Wakselman et al., 2008; Sierra et al., 2010; Lee and Landreth, 2010; Paolicelli et al., 2011; Prinz et al., 2011)."
path(MESH:Apoptosis) -> a(NCIT:C120869)
SET MeSHAnatomy = "Central Nervous System"
composite(a(MESH:Microglia), a(NCIT:C120869))
UNSET MeSHAnatomy
a(MESH:Microglia) -| a(MESH:Synapses)
a(MESH:Microglia) -| path(MESH:"Protein Aggregation, Pathological")

SET Evidence = "However, recent studies indicate that this process re-activates in Alzheimer’s disease (AD), in which amyloid promotes microglia-mediated removal of synapses (Hong et al., 2016)."
#this process - synaptic pruning
path(DOID:"Alzheimer's disease") => path(MESH:"Neuronal Plasticity")
SET MeSHDisease = "Alzheimer Disease"
p(HGNC:APP) -> a(MESH:Microglia)
a(MESH:Microglia) =| a(MESH:Synapses)
UNSET MeSHDisease

SET Evidence = "Synaptic loss, an early and highly predictive correlate of cognitive decline (Terry et al., 1991), occurs not only in AD but also in other distinct neurodegenerative disorders characterized by the presence of toxic protein aggregates."
path(MESH:"Neuronal Plasticity") pos path(MESH:"Cognitive Dysfunction")
path(MESH:"Protein Aggregation, Pathological") -- path(DOID:"neurodegenerative disease")
path(MESH:"Neuronal Plasticity") -- path(DOID:"neurodegenerative disease")

SET Evidence = "Evidence from genome-wide association studies (GWASs) reveals that most genes associated with risk to develop such disorders are highly expressed in microglia, which implies that they could modulate immune and phagocytic functions in disease states (Derecki et al., 2014)."
a(MESH:Microglia) reg path(MESH:"Immune System")
a(MESH:Microglia) reg path(MESH:Phagocytosis)

SET Evidence = "Microglia, the scavenger cells of the brain, play a key role as moderators of protein aggregates clearance, which occurs intracellularly through enzymatic degradation following phagocytosis or extracellularly through degradation by secreted enzymes (Vekrellis et al., 2000; Nakanishi, 2003; Ries and Sastre,
2016; Sole´ -Dome` nech et al., 2016)."
a(MESH:Microglia) reg deg(p(CONSO:"protein aggregates"))
a(MESH:Enzymes) -> deg(p(CONSO:"protein aggregates"))
deg(p(CONSO:"protein aggregates")) -> path(MESH:Phagocytosis)

SET Evidence = "TDP-43 exhibited the strongest Abeta clearance in BV2 cells, i.e., residual Abeta peptide levels measured from medium containing endogenous murine Abeta showed a significant reduction after exposure to cells in which TDP-43 gene was knocked down (Figures S1A–S1D)."
#BV2 cells
p(HGNC:TARDBP) => deg(p(MESH:"Amyloid beta-Peptides"))

SET Evidence = "TDP-43 is a 43 kDa DNA-RNA binding protein encoded by the Tardbp gene and is a known transcriptional repressor, mRNA binding protein, and splicing factor (Buratti and Baralle, 2001; Lagier-Tourenne et al., 2010; Polymenidou et al., 2011; Baralle et al.,2013)."
p(HGNC:TARDBP) isA p(MESH:"RNA-Binding Proteins")
p(HGNC:TARDBP) isA p(MESH:"DNA-Binding Proteins")
g(HGNC:TARDBP) -> p(HGNC:TARDBP)
p(HGNC:TARDBP) isA p(MESH:"Repressor Proteins")
p(HGNC:TARDBP) -> act(p(HGNC:TARDBP), ma(GO:"mRNA binding"))
p(HGNC:TARDBP) isA a(MESH:"RNA Splicing Factors")

SET Evidence = "Ubiquinated TDP-43 aggregates represent the predominant constituent of cytoplasmic inclusions in glia and neurons in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) patients, who show severe neuronal loss in frontal or motor cortex, respectively (Neumann et al., 2006)."
SET Cell = {"glial cell", "neuron"}
path(OMIT:0026893) -> p(HGNC:TARDBP, pmod(CONSO:"protein aggregation"), pmod(Ub), loc(MESH:"Inclusion Bodies"))
path(DOID:"amyotrophic lateral sclerosis") -> p(HGNC:TARDBP, pmod(CONSO:"protein aggregation"), pmod(Ub), loc(MESH:"Inclusion Bodies"))
UNSET Cell
SET Cell = "neuron"
path(OMIT:0026893) neg a(MESH:"Frontal Lobe")
path(DOID:"amyotrophic lateral sclerosis") neg a(MESH:"Motor Cortex")
UNSET Cell

SET Evidence = "The accompanying cell death in these disorders may arise from a combination of a toxic gain of function and a loss of nuclear TDP-43, both of which are associated with the presence of cytoplasmic aggregates (Cohen
et al., 2011; Gendron and Petrucelli, 2011)."
#these disorders - ALS, FTLD
SET MeSHDisease = {"Amyotrophic Lateral Sclerosis", "Frontotemporal Lobar Degeneration"}
p(HGNC:TARDBP, loc(GO:nucleus)) -| bp(GO:"cell death")
p(HGNC:TARDBP, pmod(CONSO:"protein aggregation"), loc(GO:cytosol)) =| p(HGNC:TARDBP, loc(GO:nucleus))
p(HGNC:TARDBP, pmod(CONSO:"protein aggregation"), loc(GO:cytosol)) => act(p(HGNC:TARDBP))
p(HGNC:TARDBP, pmod(CONSO:"protein aggregation"), loc(GO:cytosol)) => bp(GO:"cell death")
act(p(HGNC:TARDBP)) => bp(GO:"cell death")
UNSET MeSHDisease

SET Evidence = "TDP-43 loss of function in neurons has been shown to be sufficient for inducing neuronal loss, accompanied by neuropathological alterations (Kraemer et al., 2010; Wu et al., 2012; Iguchi et al., 2013; Vanden Broeck et al., 2013)"
SET Cell = "neuron"
act(p(HGNC:TARDBP)) -| bp(GO:"cell death")
bp(GO:"cell death") -> path(MESH:Neuropathology)
UNSET Cell

SET Evidence = "These results indicate that TDP-43 depletion in microglia increases the overall phagocytic activity."
SET Cell = "microglial cell"
p(HGNC:TARDBP) -| path(MESH:Phagocytosis)
UNSET Cell

SET Evidence = "Since TDP-43 depletion increased intracellular degradation and amyloid is sorted to the lysosomal compartment for degradation in microglia (Cole et al., 1992), we examined whether increased lysosomal
function occurs after TDP-43 depletion"
SET Cell = "microglial cell"
p(HGNC:TARDBP) -| path(MESH:Phagocytosis)
p(HGNC:TARDBP) -| deg(p(HGNC:APP, loc(GO:lysosome)))
UNSET Cell

SET Evidence = "In addition, increased levels of lysosomal markers, such as LAMP1 and LAMP2, also accompanied the increased changes in acidic organelles in both BV2 cells (Figure 1M) and primary microglia cultures depleted of TDP-43 (Figures S3A–S3C)."
#BV2 cell, primary microglia cultures
p(HGNC:TARDBP) -| p(HGNC:LAMP1)
p(HGNC:TARDBP) -| p(HGNC:LAMP2)
p(HGNC:TARDBP) -| bp(GO:"lysosomal lumen acidification")

SET Evidence = "TDP-43 loss was recently shown to promote the nuclear translocation of TFEB, a transcription factor regulating lysosomal biogenesis (Xia et al., 2016)."
p(HGNC:TARDBP) -| tloc(p(HGNC:TFEB), fromLoc(GO:cytosol), toLoc(GO:nucleus))
SET CellStructure = "Lysosomes"
p(HGNC:TFEB) reg path(MESH:"Organelle Biogenesis")
UNSET CellStructure

SET Evidence = "We found that the expression of Lamp1, CtsD, CtsB, Clcn7, vATP6v1h, Psap, and Psen2 in TDP-43-depleted cells was higher than in scrambled control (Figure S3D)."
#gene expression
p(HGNC:TARDBP) -| r(HGNC:LAMP1)
p(HGNC:TARDBP) -| r(HGNC:CTSD)
p(HGNC:TARDBP) -| r(HGNC:CTSB)
p(HGNC:TARDBP) -| r(HGNC:CLCN7)
p(HGNC:TARDBP) -| r(HGNC:ATP6V1H)
p(HGNC:TARDBP) -| r(HGNC:PSAP)
p(HGNC:TARDBP) -| r(HGNC:PSEN2)


SET Evidence = "We confirmed that Tardbp transcript levels were significantly downregulated specifically in microglia isolated from cKO mice upon tamoxifen administration compared to WT controls, whereas overall cortical
levels remained unchanged (Figures S4A and S4B)."
#conditional TDP-43 knockout mouse line (cKO)
composite(a(CHEBI:tamoxifen), a(MESH:Microglia)) =| p(HGNC:TARDBP)
composite(a(CHEBI:tamoxifen), a(MESH:Microglia)) cnc a(MESH:"Cerebral Cortex")

SET Evidence = "These results definitely show that TDP-43 depletion in microglia promotes Abeta clearance,
rather than affecting production."
SET Cell = "microglial cell"
p(HGNC:TARDBP) -| deg(p(HGNC:APP))
p(HGNC:TARDBP) cnc p(HGNC:APP)
UNSET Cell

#condition - decrease in amyloid load

SET Evidence = "Specifically, PSD95, a scaffold protein located in dendritic spines, was significantly reduced (Figure 3F), while levels of MAP2, a dendritic structural protein, were comparable between WT and cKO mice"
SET CellStructure = "Dendritic Spines"
deg(p(HGNC:APP)) =| p(HGNC:DLG4)
UNSET CellStructure
SET CellStructure = "Dendrites"
deg(p(HGNC:APP)) cnc p(HGNC:MAP2)
UNSET CellStructure

SET Evidence = "Consistently, levels of synapsin and synaptophysin were also reduced (Figures 3H and 3I)."
deg(p(HGNC:APP)) -| p(HGNCGENEFAMILY:Synapsins)
deg(p(HGNC:APP)) -| p(HGNCGENEFAMILY:Synaptophysins)

SET Evidence = "In addition, quantification of immunoreactive puncta for the synaptic marker vGlut1 also confirmed a drastic reduction in glutamatergic terminals (Figures 3J and 3K)."
deg(p(HGNC:APP)) -| bp(GO:"synaptic transmission, glutamatergic")

SET Evidence = "These data show that microglia lacking TDP-43 can mediate enhanced removal and clearance
of amyloid in an AD mouse model, but also in parallel, induce significant synapse loss."
SET Cell = "microglial cell"
SET Species = "10090"
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:TARDBP) -| deg(p(HGNC:APP))
p(HGNC:TARDBP) -> a(MESH:Synapses)
UNSET MeSHDisease
UNSET Species
UNSET Cell

#end of condition

SET Evidence = "Microglia are shown to re-activate synaptic pruning in the presence of Abeta oligomers (Hong et al., 2016)."
a(MESH:Microglia, loc(CONSO:"amyloid-beta oligomers")) -> path(MESH:"Neuronal Plasticity")

#in case of synaptic loss

SET Evidence = "Since demyelination can occur in many neurodegenerative disorders, we also assayed levels of myelin binding protein (MBP) isoforms and found a significant decrease (Figures 4A and 4D)."
path(MESH:"Neuronal Plasticity") =| p(HGNC:MBP)

SET Evidence = "The decrease in PSD95 was significant despite no changes in MAP2 levels, indicative of a selective synapse loss rather than general neuronal death (Figures 4A and 4E)."
p(HGNC:MAP2) cnc p(HGNC:DLG4)
path(MESH:"Neuronal Plasticity") =| p(HGNC:DLG4)

SET Evidence = "These results conclusively show that synapse loss occurs due to microglial TDP-43 depletion in
mice, independent of amyloid load."
SET Cell = "microglial cell"
p(HGNC:TARDBP, loc(CONSO:"amyloid-beta oligomers")) -> path(MESH:"Neuronal Plasticity")
p(HGNC:TARDBP) -> path(MESH:"Neuronal Plasticity")
UNSET Cell

#end of case

SET Evidence = "This suggests that TDP-43 pathology might promote neurodegeneration through synapse loss on one
hand, but on the other might also reduce the risk for enhancing the amyloid load and thus decrease the prevalence of AD."
path(MESH:"TDP-43 Proteinopathies") -> path(EFO:"neurodegenerative disease")
path(MESH:"TDP-43 Proteinopathies") -> deg(p(HGNC:APP))
path(MESH:"TDP-43 Proteinopathies") -| path(DOID:"amyotrophic lateral sclerosis")

SET Evidence = "Importantly, we found that CD68 burden was significantly higher in ALS patients with TDP-43 pathology as compared to ALS patients without TDP-43 inclusions, or to healthy controls (Figures 5E and 5F; Table S2), supporting a critical role for TDP-43 in regulating microglial function."
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
path(MESH:"TDP-43 Proteinopathies") => p(HGNC:CD68)
UNSET MeSHDisease
path(DOID:"amyotrophic lateral sclerosis") -> p(HGNC:CD68)
p(HGNC:TARDBP) reg act(a(MESH:Microglia))

SET Evidence = "In the MND cases, but not in the controls, we could observe examples of cytoplasmic inclusions positively stained for phospho-TDP-43 (pTDP-43) within microglial cells positive for Iba1 (Figure 5G), indicating that microglial TDP-43 can contribute to TDP-43 pathology."
#MND : motor neurodegenerative
path(DOID:"motor neuron disease") -> composite(a(MESH:Microglia), p(HGNC:TARDBP))
composite(a(MESH:Microglia), p(HGNC:TARDBP)) -> path(MESH:"TDP-43 Proteinopathies")

#UNSET Species
